Suven Life Sciences Limited's Board of Directors formally approved the conversion of 3,17,68,764 warrants into equity shares at ₹134 per share during their meeting on March 6, 2026. The allotment to promoter group entity JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED raised ₹425.70 crore and increased the company's paid-up equity capital from ₹23.19 crore to ₹26.37 crore, demonstrating strong promoter confidence and providing enhanced financial resources for strategic growth.
Suven Life Sciences Board Approves ₹425.70 Crore Warrant Conversion
Suven Life Sciences Limited's Board of Directors has formally approved the conversion of warrants into equity shares, completing a significant capital raising exercise. The board meeting held on March 6, 2026, resulted in the allotment of equity shares to a promoter group entity, strengthening the company's financial position.
Board Meeting Outcome
The Board of Directors meeting, which commenced at 11:00 AM IST and concluded at 11:20 AM IST on March 6, 2026, approved the conversion of fully paid warrants into equity shares. The conversion was executed in accordance with SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018.
Parameter: Details Meeting Date: March 6, 2026 Warrants Converted: 3,17,68,764 Issue Price: ₹134 per share Total Consideration: ₹425,70,14,376
Allotment Details
The company has allotted 3,17,68,764 equity shares of ₹1 each to JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED in its capacity as sole trustee of Jasti Family Trust. This promoter group entity has provided 100% consideration amount aggregating to ₹425,70,14,376 in compliance with regulatory requirements.
Allottee: Shares Allotted JASTI PROPERTY AND EQUITY HOLDINGS PRIVATE LIMITED: 3,17,68,764 (As sole trustee of Jasti Family Trust):
Capital Structure Impact
The warrant conversion has resulted in a significant expansion of the company's equity base. The paid-up equity share capital has increased substantially following the allotment.
Capital Structure: Before Allotment After Allotment Equity Shares: 23,19,51,819 26,37,20,583 Amount (₹): 23,19,51,819.00 26,37,20,583.00
Regulatory Compliance
The allotment was conducted as a preferential issue in accordance with Chapter V of the SEBI (ICDR) Regulations, 2018. The company has fulfilled all disclosure requirements pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, ensuring complete transparency in the process.
This successful warrant conversion demonstrates strong promoter confidence and provides Suven Life Sciences with enhanced financial resources to pursue its strategic objectives in the pharmaceutical sector.
Suven Life Sciences Limited has issued a formal clarification to BSE Limited addressing recent price movements in its stock. The communication, dated February 6, 2026, was submitted in response to BSE's surveillance inquiry regarding unusual price activity.
Company's Response to BSE Surveillance
The pharmaceutical company clarified its position through a detailed response to BSE's surveillance department. The clarification was prompted by BSE's inquiry reference L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 dated February 5, 2026.
Parameter Details Communication Date February 6, 2026 BSE Scrip Code 530239 Reference Number L/SURV/ONL/PV/AJ/ 2025-2026 / 3355 Signatory K. Sangeetha Laxmi, Company Secretary
Regulatory Compliance Statement
Suven Life Sciences emphasized its commitment to regulatory compliance, stating that the company has been consistently notifying stock exchanges of all material events and information falling under Regulation 30 of SEBI (LODR) Regulations, 2015. The company maintained that it follows proper disclosure protocols for all significant developments.
The management confirmed that no material announcements or events are currently pending notification to stock exchanges under SEBI regulations that could influence the stock's price or volume behavior.
Market Speculation Attribution
The company attributed recent price and volume movements to market speculation rather than any undisclosed material information. Suven Life Sciences stated it has no additional comments regarding the recent market developments affecting its stock performance.
The clarification has been made available to the general public through dissemination on BSE's website and the company's official website, ensuring transparency in communication with stakeholders.
We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better.
Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians.
As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.